FindTrial
Sign In

Exploratory human PET study with 11C-(S)ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes for Alzheimer's disease

Exploratory human PET study with 11C-(S)ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes for Alzheimer's disease - KET-3

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016486
Enrollment
21
Registered
2015-02-09
Start date
2014-04-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

The dosage in the vein of [11C] ketoprofen methylester for PET imaging. The dosage in the vein of [11C] ketoprofen methylester for PET imaging. The dosage in the vein of [11C] ketoprofen methylester f

Sponsors

Institute of Biomedical Research and Innovation
Lead Sponsor
RIKEN Kobe University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Step1 1. The subject who has intention to participate in this study, and singed informed consent. 2. Age >=20 and <45 years old, with body weight >=50kgt and <85kg, and BMI >=17.6 and <26.4. 3. The subject who was judged by clinical investigator by means of physical examination and Laboratory tests to be eligible as a participant in this study. Step2 1. The subject who has intention to participate in this study, and singed informed consent. 2. Age >=55 years old, body weight >=50kgt and <85kg, and BMI >=17.6 and <26.4. 3. The subject who was judged by clinical investigator by means of physical examination and Laboratory tests to be eligible as a participant in this study. 4.In healthy subjects, MRI findings is age-appropriate normal or there is no change to be a clinical problem. In patients, subjects who do not have disease that causes cognitive impairment except MCI and AD by MRI.

Exclusion criteria

Exclusion criteria: 1)The subject who has a peptic ulcer. 2)The subject who has blood abnormality. 3)The subject who has dysfunction in the liver / kidney. 4)The subject who has cerebrovascular disorder. 5)The subject having cardiac failure. 6)The subject with WPW or LGL syndrome, or marked bradycardia, in electrocardiogram. 7)The subject with a history of a drug or food allergy. 8)The subject who was judged by the clinical investigator to be inappropriate as a participant in this study.

Design outcomes

Primary

MeasureTime frame
Retention and uptake of [11C](S)ketoprofen methyl ester in patients with Alzheimer's disease—

Countries

Japan

Contacts

Public ContactAkihito Ohnishi

Institute of Biomedical Research and Innovation Division of Molecular Imaging

ohnishi@fbri.org078-304-5212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026